We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
20 Oct 2021 - 22 Oct 2021
21 Oct 2021 - 24 Oct 2021
Virtual Venue

Whole-Genome Sequencing Applied to Acutely Ill Infants

By LabMedica International staff writers
Posted on 12 Oct 2021
Print article
Image: Effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease investigated (Photo courtesy of Illumina)
Image: Effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease investigated (Photo courtesy of Illumina)
Critically ill infants admitted to an intensive care unit are at risk for high levels of morbidity and mortality. In the USA, approximately 400,000 newborns are admitted to a neonatal ICU annually, costing at least USD 26 billion and accounting for up to 50% of the total national pediatric health care expenditure.

Genetic disorders are a leading cause of ICU admission, and recent studies have used comprehensive genomic testing in populations of acutely ill infants, using either whole-exome sequencing, which surveys approximately 2% of the genome that codes for proteins, or whole-genome sequencing (WGS), which evaluates approximately 95% of nuclear and mitochondrial DNA.

Medical Scientist at six children’s hospital (NICU-Seq trial) collaborated with the sequencing company Illumina and conducted a randomized time-delayed clinical trial, with a diverse population of 354 infants to receive Whole-Genome Sequencing (WGS) either 15 days or 60 days after enrollment. Infants' mean age was 15 days in the full 354-member sample. About 57% were boys, 71% were white, and 23% were Hispanic (either white or Black).

Clinical whole genome testing was performed by the Illumina Clinical Services Laboratory (ICSL, San Diego CA USA). Whole genome sequencing was performed on extracted DNA using sequencing-by-synthesis (SBS) next generation sequencing (NGS). The data were aligned and reported using build 37.1 of the Human Reference Genome. The genome was sequenced to an average of 38.9 fold coverage (IQR 37.3-39.77) and an average of 97.9% of the genome was callable (IQR 97.5-98.1).

The team reported that the largest number of diagnoses were in infants with multiple congenital anomalies (63/191; 33%), and the highest proportion were those with a single major clinical feature (19/35; 54%) Some 15% had a neurological disorder, and 11% had just a single major feature prompting the desire for testing. Infants with an isolated major congenital anomaly were the least likely to receive a positive finding from sequencing.

In addition to the primary outcome assessment at day 60, The scientists were able to follow almost all the sample out to day 90, by which point the control group had also undergone sequencing. At that point, another four infants in the original intervention group had a change in management; in the control group, meanwhile, another 28 infants had a new care plan, presumably based on the sequencing results for most of them.

One positive finding the authors called "unexpected" was that, among 32 extremely and very premature infants, whole genome sequencing identified a likely cause of their illness in nine (28.1%), suggesting that sequencing may have broad applicability in premature neonates.

The authors concluded that they found that two-thirds of patients received a change of management (COM) regardless of the testing modality, suggesting that the 2-fold higher diagnostic efficacy of systematically applied first-line WGS in acute infant care could reduce health care disparities. The study was published on September 27, 2021 in the JAMA Pediatrics.

Related Links:
Illumina Clinical Services Laboratory

New
Gold Supplier
Hemostasis Analyzer
STA R Max 3
New
Laboratory Automation System
FlexLab Automation
New
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit

Print article

Channels

Clinical Chem.

view channel
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)

Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease

Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)

Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and... Read more

Immunology

view channel
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)

Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. One of the cornerstones... Read more

Pathology

view channel
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)

Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. DAH can induce severe respiratory... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.